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toxicities. Longer follow-up is needed to confirm these 
early results.  
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Purpose or Objective  
Single fraction ultrasound-based high-dose-rate brachy-
therapy (HDR-BT) as monotherapy for low-risk prostate 
cancer (PCa) compared to multiple fractions, will 
improve patient comfort and treatment accuracy and 
save time, costs and human resources. Moreover, it is 
also expected to decrease toxicity rates with similar 
clinical outcome. However, there is no clear evidence 
which dose level will result in the best outcome. 
Therefore, we performed a planning study to investigate 
the best dose level of single fraction HDR-BT. 
Material and Methods  
Ultrasound-based plans of 26 consecutive patients with 
low-risk PCa (n=19 treated with 4 fractions of 9.5 Gy; n=4 
with 1 fraction of 19.0 Gy and n=3 with 1 fraction of 13.0 
Gy; treated between October 2016 and August 2017) 
were used to generate new treatment plans for three 
fractionation schemes, using the existing needle 
geometry: 1 x 19.0 Gy, 1 x 19.5 Gy and 1 x 20.0 Gy.  
All plans were optimized according to the following 
objectives: 
Prostate: V100% ≥ 95% and D90% ≥ 100% PD (Prescribed 
Dose) 
Bladder: D1cc < 16.0 Gy and D2cc < 15.5 Gy  
Rectum D1cc < 15.5 Gy and D2cc < 14.5 Gy  
Urethra D0.1cc < 21.0 Gy and D10% < 20.5 Gy and V120% 
in 0 cc 
The coverage of the prostate was maximized considering 
the dose constraints for the organs at risk.   
The V100%(%), D90%(Gy) and V22.8Gy(%) (120% of 19.0 
Gy) were used to evaluate the 78 treatment 
plans.Results  
The mean prostate V100% for the 19.0, 19.5 and 20.0 Gy 
schemes was 95.0%, 94.3% and 91.5% respectively with 
69.2%, 50.0% and 7.7% of the plans meeting the objective 
of V100% ≥ 95%.   
The urethra D10% was the limiting factor for meeting the 
V100% objective in respectively 73%, 50% and 50% of the 
plans.  
The D90% increased for the 19.5 Gy plans compared to 
the 19.0 Gy dose schedule with a mean of 0.3 Gy with 
96.2% of these plans meeting the objective D90% ≥ 
100%PD.  
The D90% decreased in the 20.0 Gy plans by a mean of 
0.2 Gy compared to plans with a prescribed dose of 19.5 
Gy.  
The V22.8Gy increased for the 19.5 Gy plans by a mean of 
3.2% compared to 19.0 Gy plans and dropped for the 20.0 
Gy plans by a mean of 1.3% compared to the 19.5 Gy 
plans (see table 1 for ranges and figure 1).  
 
 




Figure 1 V22.8Gy (%) for three fractionation schemes 
Conclusion  
With both a higher mean D90% and a higher mean 
V22.8Gy in the 19.5 Gy plans compared to the other two 
dose levels, in this planning study, the 19.5 Gy seems to 
be the dose level we should focus on. However, the 
absolute dose differences are limited and the question 
remains whether or not these dose differences are 
clinically relevant. 
Further increase in the number of plans meeting the 
V100% objective is necessary and can most likely be done 
by a slight improvement of the needle configuration. 
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Purpose or Objective  
Edema evolution following seeds’ implantation is not 
considered during low-dose-rate (LDR) prostate 
brachytherapy inverse planning. Commonly, planning is 
performed after inserting the peripheral needles, when 
edema has occurred. Hence, the selected plan can result 
in increased toxicity due to seeds’ migration during 
edema resorption after implantation. In this work, we 
propose a strategy to adapt intraoperative inverse 
planning based on edema resorption effects. A previously 
developed edema biomechanical model was introduced in 
an in-house inverse planning system. A dose-volume-
histogram (DVH) based optimization algorithm combined 
with Monte Carlo dosimetry was used for implant 
optimization. 
Material and Methods  
To account for edema, a biomechanical model based on 
the biphasic theory was previously developed. Edema 
formation is simulated by a linear pressure increase in 
prostate’s fluid compartment. Resorption is exclusively 
driven from the prostate’s elastic response in a time-span 
of 30 days. The model is solved with the Finite Elements 
Method on a tetrahedral mesh of the patient’s transrectal 
ultrasound (TRUS) image. In a simulation scenario with 63 
kPa fluid pressure and 50 kPa prostate Young Modulus, 
edema magnitude is at 40% during the operation and 3% 
after 30 days. A plan is generated for intraoperative 
prostate volume (40% edema) and postoperative 
dosimetry at day 30 is performed assuming linear seeds’ 
migration due to edema resorption. To account for 
edema resorption during planning, a volume resampling 
algorithm is used to deform the intraoperative TRUS 
image and apply edema-related seeds’ migration to the 
candidate implantation sites selected during the intra-
operative planning. MC dose kernels are calculated for 
each migrated candidate site. Dose evaluation during 
implant optimization is performed minimizing the 
variation of DVH metrics from the AAPM TG-137 
